Aptamers can be conjugated to drug molecules or nanoparticles to enable targeted drug delivery. The aptamer directs the drug to the desired tissue or cell type, reducing off-target effects and ...

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science ...

The companies are developing a rapid, at-home colorectal cancer test that uses interstitial fluid as a sample type.

By combining the aptamer with a nanoparticle ... and can be easily adaptable for the release of oligonucleotides of different ...

These include an aptamer that targets interferon-γ with ... small-interfering RNAs and antisense oligonucleotides to specific cell types. Xenoligo is also useful for affinity chromatography.

After 72 hours, the aptamer alone had reduced the cancer cells ... we can target other cancer types as well. Also, in my experience, it’s much easier to pair a drug with the DNA molecules ...

Aptamer will receive a 10 per cent royalty on all future revenues from any vaccines incorporating the licensed Optimers, creating a scalable, global, non-dilutive revenue stream. Dr Arron Tolley ...

Life sciences company Aptamer Group has signed a licensing agreement with the University of Glasgow for exclusive rights to its synthetic binders to develop swine flu vaccines. Under the agreement ...

reversed the effects of the aptamer on activated clotting time without any signs of toxicity. Although the safety of this type of agent will have to be further tested in clinical studies ...